Roland Zahn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roland Zahn has a total of 522 co-authors. Here are the top co-authors by number of shared publications:
- Hanneke Schuitemaker
Janssen Vaccines & Prevention B.V., Leiden, Netherlands
26 shared publications - Frank Wegmann
Janssen Vaccines & Prevention, Leiden, the Netherlands
24 shared publications - Dan H. Barouch
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
18 shared publications Jan Serroyen
Johnson & Johnson, Leiden, The Netherlands
15 shared publications- Catherine Jacob-Dolan
Division of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA
11 shared publications - Laura Solforosi
Janssen Vaccines & Prevention B.V., Leiden, The Netherlands
10 shared publications
Latest Publications
- Open Access
- 23 May 2026
- Published by Springer Nature in npj Vaccines
- Vol. 11 (1)
Heterologous vaccination with a next-generation vaccinia virus and Ad26 induces Ebola-specific immunity in macaques
Different ways of combining virus vector-based vaccines can impact the effectiveness of immune responses against specific antigens. In this study, we explored the effects of different immunization schedules on immune responses elicited by viral vector-based vaccines in monkeys, with a focus on the heterologous regimens with a next-generation attenuated vaccinia virus, Sementis Copenhagen vector (SCV), and human adenovirus serotype 26 (Ad26) expressing the Ebola glycoprotein (EBOV-GP). Our findings highlight that the order of administration of these vaccines plays a pivotal role in modulating cellular immune responses. We observed that initiating immunization with Ad26.EBOV followed by SCV.EBOV, significantly enhanced the magnitude and quality of antigen-specific memory CD4+ T-cell responses when compared to a homologous Ad26.EBOV regimen. Importantly, the binding antibody titers induced by this heterologous approach were similar to that elicited by a homologous Ad26.EBOV regimen, although we observed a transiently elevated neutralizing antibody titers at the peak of the response for the SCV.EBOV/Ad26.EBOV regimen. Our results suggest that a heterologous vaccination strategy combining Ad26.EBOV and SCV.EBOV could be an alternative to the currently used Ad26/MVA platform for Ebola vaccination, potentially mitigating some of the manufacturing challenges associated with Modified Vaccinia virus Ankara (MVA). The observed benefits of the heterologous regimen, particularly its capacity to enhance T-cell responses, reinforce its potential as a promising alternative to homologous regimens that warrants further investigation.
- 23 May 2026
- Published by Springer Nature in npj Vaccines
- Vol. 11 (1)
Open AccessHeterologous vaccination with a next-generation vaccinia virus and Ad26 induces Ebola-specific immunity in macaques
Different ways of combining virus vector-based vaccines can impact the effectiveness of immune responses against specific antigens. In this study, we explored the effects of different immunization schedules on immune responses elicited by viral vector-based vaccines in monkeys, with a focus on the heterologous regimens with a next-generation attenuated vaccinia virus, Sementis Copenhagen vector (SCV), and human adenovirus serotype 26 (Ad26) expressing the Ebola glycoprotein (EBOV-GP). Our findings highlight that the order of administration of these vaccines plays a pivotal role in modulating cellular immune responses. We observed that initiating immunization with Ad26.EBOV followed by SCV.EBOV, significantly enhanced the magnitude and quality of antigen-specific memory CD4+ T-cell responses when compared to a homologous Ad26.EBOV regimen. Importantly, the binding antibody titers induced by this heterologous approach were similar to that elicited by a homologous Ad26.EBOV regimen, although we observed a transiently elevated neutralizing antibody titers at the peak of the response for the SCV.EBOV/Ad26.EBOV regimen. Our results suggest that a heterologous vaccination strategy combining Ad26.EBOV and SCV.EBOV could be an alternative to the currently used Ad26/MVA platform for Ebola vaccination, potentially mitigating some of the manufacturing challenges associated with Modified Vaccinia virus Ankara (MVA). The observed benefits of the heterologous regimen, particularly its capacity to enhance T-cell responses, reinforce its potential as a promising alternative to homologous regimens that warrants further investigation.
- Open Access
- 13 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A group 1 hemagglutinin stem vaccine elicits broad humoral responses against influenza in phase 1/2a study
Vaccines targeting the conserved stem region of influenza hemagglutinin (HA) may induce broad immunity and reduce reliance on strain-matched seasonal formulations. This Phase 1/2a study evaluates safety and immunogenicity of a universal influenza vaccine component comprising a soluble trimeric stabilized group 1 HA-stem protein (INFLUENZA G1 mHA). Healthy adults aged 18-to-45 received one or two doses at 45 µg or 135 µg, with or without Al(OH)₃. Primary endpoints were safety and reactogenicity. All regimens were well-tolerated with no vaccine-related serious adverse events. Secondary and exploratory endpoints included binding, neutralizing, and ADCC responses compared to a matched quadrivalent seasonal influenza vaccine cohort. A single dose induced robust binding antibody responses to H5 HA and homologous stem HA, with 6.5-16.4-fold increases at Day 29 versus baseline, exceeding responses elicited by the seasonal influenza vaccine. Additionally, we demonstrate broader binding to a panel of group 1 HAs, with responses maintained for at least one year. Neutralizing antibody and ADCC responses at Day 29 showed 7.9-15-fold and 4.9-8.6-fold increases, respectively. Importantly, serum from vaccinated participants protect mice against lethal heterologous H5N1 challenge. This study provides proof of concept that the HA stem vaccine elicits broad and durable influenza A group 1-directed immunity. This trial is registered with ClinicalTrials.gov (NCT05901636).
- 13 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA group 1 hemagglutinin stem vaccine elicits broad humoral responses against influenza in phase 1/2a study
Vaccines targeting the conserved stem region of influenza hemagglutinin (HA) may induce broad immunity and reduce reliance on strain-matched seasonal formulations. This Phase 1/2a study evaluates safety and immunogenicity of a universal influenza vaccine component comprising a soluble trimeric stabilized group 1 HA-stem protein (INFLUENZA G1 mHA). Healthy adults aged 18-to-45 received one or two doses at 45 µg or 135 µg, with or without Al(OH)₃. Primary endpoints were safety and reactogenicity. All regimens were well-tolerated with no vaccine-related serious adverse events. Secondary and exploratory endpoints included binding, neutralizing, and ADCC responses compared to a matched quadrivalent seasonal influenza vaccine cohort. A single dose induced robust binding antibody responses to H5 HA and homologous stem HA, with 6.5-16.4-fold increases at Day 29 versus baseline, exceeding responses elicited by the seasonal influenza vaccine. Additionally, we demonstrate broader binding to a panel of group 1 HAs, with responses maintained for at least one year. Neutralizing antibody and ADCC responses at Day 29 showed 7.9-15-fold and 4.9-8.6-fold increases, respectively. Importantly, serum from vaccinated participants protect mice against lethal heterologous H5N1 challenge. This study provides proof of concept that the HA stem vaccine elicits broad and durable influenza A group 1-directed immunity. This trial is registered with ClinicalTrials.gov (NCT05901636).
- Open Access
- 17 March 2026
- Published by Wiley in Clinical & Translational Immunology
- Vol. 15 (3)
An Ad26‐ MVA ‐ BN ‐based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections
Objectives: To develop a therapeutic human papillomavirus (HPV) vaccine capable of intercepting HPV‐related cervical disease to reduce the number of new cancer cases and associated deaths. Methods: We previously reported that replication‐deficient adenovirus type 26 and 35‐based vectors (Ad26, Ad35) expressing a fusion protein of E2, E6 and E7 (E2SH) from HPV16 and HPV18 induced robust HPV‐specific T‐cell immunity capable of reducing HPV16+ tumors in mice. Here, we assessed immune responses induced by Ad26 and Modified Vaccinia Virus Ankara—strain Bavarian Nordic (MVA‐BN) viral vectors expressing E2SH in heterologous vaccination regimens in mice, macaques and a limited number of persistently HPV‐infected women ( N = 5). Results: The magnitude and breadth of cellular immune responses were higher in mice that received Ad26.HPV16/18‐MVA‐BN.HPV16/18 than in those that received Ad26.HPV16/18‐Ad35.HPV16/18, all expressing the fusion protein E2SH of HPV16 and HPV18. Sustained and broad antigen‐specific systemic T‐cell responses against HPV16 and HPV18 proteins were induced in macaques. In the Phase 1/2a trial, a 2‐dose heterologous immunisation with Ad26.HPV16 or Ad26.HPV18 in Week 0 and MVA‐BN.HPV16/18 in Week 8 induced long‐lived antigen‐specific cytokine‐producing T cells. After Week 8, HPV16/18 infection was no longer detected in 5/5 active vaccines and 1/4 placebo recipients during the study period of approximately 1 year. The small number of vaccinated participants did not allow concluding on the relationship between immune responses and viral clearance. Conclusion: These data show the ability of Ad26.HPV16/18‐MVA‐BN.HPV16/18 heterologous regimens to elicit HPV‐specific T‐cell responses and warrant further clinical studies to evaluate vaccine efficacy.
- 17 March 2026
- Published by Wiley in Clinical & Translational Immunology
- Vol. 15 (3)
Open AccessAn Ad26‐ MVA ‐ BN ‐based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections
Objectives: To develop a therapeutic human papillomavirus (HPV) vaccine capable of intercepting HPV‐related cervical disease to reduce the number of new cancer cases and associated deaths. Methods: We previously reported that replication‐deficient adenovirus type 26 and 35‐based vectors (Ad26, Ad35) expressing a fusion protein of E2, E6 and E7 (E2SH) from HPV16 and HPV18 induced robust HPV‐specific T‐cell immunity capable of reducing HPV16+ tumors in mice. Here, we assessed immune responses induced by Ad26 and Modified Vaccinia Virus Ankara—strain Bavarian Nordic (MVA‐BN) viral vectors expressing E2SH in heterologous vaccination regimens in mice, macaques and a limited number of persistently HPV‐infected women ( N = 5). Results: The magnitude and breadth of cellular immune responses were higher in mice that received Ad26.HPV16/18‐MVA‐BN.HPV16/18 than in those that received Ad26.HPV16/18‐Ad35.HPV16/18, all expressing the fusion protein E2SH of HPV16 and HPV18. Sustained and broad antigen‐specific systemic T‐cell responses against HPV16 and HPV18 proteins were induced in macaques. In the Phase 1/2a trial, a 2‐dose heterologous immunisation with Ad26.HPV16 or Ad26.HPV18 in Week 0 and MVA‐BN.HPV16/18 in Week 8 induced long‐lived antigen‐specific cytokine‐producing T cells. After Week 8, HPV16/18 infection was no longer detected in 5/5 active vaccines and 1/4 placebo recipients during the study period of approximately 1 year. The small number of vaccinated participants did not allow concluding on the relationship between immune responses and viral clearance. Conclusion: These data show the ability of Ad26.HPV16/18‐MVA‐BN.HPV16/18 heterologous regimens to elicit HPV‐specific T‐cell responses and warrant further clinical studies to evaluate vaccine efficacy.
- Open Access
Adenovector 26 Encoded RSV Prefusion F Protein (Ad26.RSV.preF) Does Not Predispose to Enhanced Respiratory Disease in Preclinical Rodent Models
Background/objectives: RSV is a major cause of mortality in infants, and despite recent progress to prevent RSV in the very young, an RSV vaccine for this population is still highly warranted. Clinical studies in infants in the 1960s using formalin-inactivated RSV (FI-RSV) led to life-threatening enhanced respiratory disease (ERD). Therefore, a thorough safety assessment of RSV vaccine candidates intended for RSV seronegative infants is crucial. Methods: Prior to clinical pediatric development of Ad26.RSV.preF, an adenovirus type 26 vector-encoding RSV F protein stabilized in its prefusion conformation, predisposition to ERD was extensively assessed in cotton rat and mouse models. Results: Cotton rats intramuscularly immunized with a wide dose range of Ad26.RSV.preF, including low and sub-protective vaccine doses, and challenged with vaccine homologous RSV A2 or heterologous RSV B Wash 18537, did not show signs of predisposition to ERD. Histopathology scores for alveolitis, peribronchiolitis, interstitial pneumonia, and perivasculitis after challenge were significantly lower for Ad26.RSV.preF-immunized cotton rats compared to FI-RSV-immunized cotton rats and comparable to or lower than scores in cotton rats intranasally pre-exposed to RSV prior to challenge to mimic natural repeated infection. These results were observed in animals with or without viral replication in the lung after RSV challenge, in the presence or absence of vaccine-induced antibodies. Similar results were observed in mice, where more extensive assessment of mono- and polymorphonuclear cell alveolitis, mucus cell hyperplasia, and mucus accumulation was performed. Conclusions: Based on these extensive analyses, we conclude that there are no indications of ERD predisposition after Ad26.RSV.preF vaccination in rodent models, irrespective of the vaccine dose, challenge virus strain, or presence of viral replication in the lung. These results are crucial for the pediatric development of this vaccine.
Open AccessAdenovector 26 Encoded RSV Prefusion F Protein (Ad26.RSV.preF) Does Not Predispose to Enhanced Respiratory Disease in Preclinical Rodent Models
Background/objectives: RSV is a major cause of mortality in infants, and despite recent progress to prevent RSV in the very young, an RSV vaccine for this population is still highly warranted. Clinical studies in infants in the 1960s using formalin-inactivated RSV (FI-RSV) led to life-threatening enhanced respiratory disease (ERD). Therefore, a thorough safety assessment of RSV vaccine candidates intended for RSV seronegative infants is crucial. Methods: Prior to clinical pediatric development of Ad26.RSV.preF, an adenovirus type 26 vector-encoding RSV F protein stabilized in its prefusion conformation, predisposition to ERD was extensively assessed in cotton rat and mouse models. Results: Cotton rats intramuscularly immunized with a wide dose range of Ad26.RSV.preF, including low and sub-protective vaccine doses, and challenged with vaccine homologous RSV A2 or heterologous RSV B Wash 18537, did not show signs of predisposition to ERD. Histopathology scores for alveolitis, peribronchiolitis, interstitial pneumonia, and perivasculitis after challenge were significantly lower for Ad26.RSV.preF-immunized cotton rats compared to FI-RSV-immunized cotton rats and comparable to or lower than scores in cotton rats intranasally pre-exposed to RSV prior to challenge to mimic natural repeated infection. These results were observed in animals with or without viral replication in the lung after RSV challenge, in the presence or absence of vaccine-induced antibodies. Similar results were observed in mice, where more extensive assessment of mono- and polymorphonuclear cell alveolitis, mucus cell hyperplasia, and mucus accumulation was performed. Conclusions: Based on these extensive analyses, we conclude that there are no indications of ERD predisposition after Ad26.RSV.preF vaccination in rodent models, irrespective of the vaccine dose, challenge virus strain, or presence of viral replication in the lung. These results are crucial for the pediatric development of this vaccine.
- Open Access
- 31 December 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0310250
A replication-incompetent adenoviral vector encoding for HSV-2 gD2 is immunogenic and protective against HSV-2 intravaginal challenge in mice
Herpes Simplex virus (HSV) is the cause of genital herpes and no prophylactic treatment is currently available. Replication-incompetent adenoviral vectors are potent inducers of humoral and cellular immune responses in humans. We have designed an adenoviral vector type 35 (Ad35)-based vaccine encoding the HSV-2 major surface antigen gD2 (Ad35.HSV.gD2). Immunization of mice with Ad35.HSV.gD2 elicited virus neutralizing antibody titers (VNT) and cellular responses against HSV-2 and HSV-1. While immunity was lower than for CJ2-gD2, both vaccines showed 100% survival against intravaginal challenge with HSV-2 G strain and a strong inverse correlation was observed between HSV-2 infection (as measured by viral shedding) and VNT. A combination of Ad35.HSV.gD2 with Ad35 encoding for gB2 (Ad35.HSV.gB2) resulted in increased VNT and lower infection, compared with Ad35.HSV.gD2 alone. Transfer of immune serum into naïve BALB/c mice before intravaginal challenge confirmed the role of antibodies in the protection of mice against infection although other immune factors may play a role as well.
- 31 December 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0310250
Open AccessA replication-incompetent adenoviral vector encoding for HSV-2 gD2 is immunogenic and protective against HSV-2 intravaginal challenge in mice
Herpes Simplex virus (HSV) is the cause of genital herpes and no prophylactic treatment is currently available. Replication-incompetent adenoviral vectors are potent inducers of humoral and cellular immune responses in humans. We have designed an adenoviral vector type 35 (Ad35)-based vaccine encoding the HSV-2 major surface antigen gD2 (Ad35.HSV.gD2). Immunization of mice with Ad35.HSV.gD2 elicited virus neutralizing antibody titers (VNT) and cellular responses against HSV-2 and HSV-1. While immunity was lower than for CJ2-gD2, both vaccines showed 100% survival against intravaginal challenge with HSV-2 G strain and a strong inverse correlation was observed between HSV-2 infection (as measured by viral shedding) and VNT. A combination of Ad35.HSV.gD2 with Ad35 encoding for gB2 (Ad35.HSV.gB2) resulted in increased VNT and lower infection, compared with Ad35.HSV.gD2 alone. Transfer of immune serum into naïve BALB/c mice before intravaginal challenge confirmed the role of antibodies in the protection of mice against infection although other immune factors may play a role as well.
- Open Access
Recombinant Anti-PF4 Antibodies Derived from Patients with Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Facilitate Research and Laboratory Diagnosis of VITT
Background/Objectives: Adenoviral vector-based vaccines against COVID-19 rarely cause vaccine-induced immune thrombocytopenia and thrombosis (VITT), a severe adverse reaction caused by IgG antibodies against platelet factor 4 (PF4). To study VITT, patient samples are crucial but have become a scarce resource. Recombinant antibodies (rAbs) derived from VITT patient characteristic amino acid sequences of anti-PF4 IgG are an alternative to study VITT pathophysiology. Methods: Amino acid sequences of the variable region of immunoglobulin light and heavy chain of anti-PF4 IgG derived from VITT patients were obtained by mass spectrometry sequencing and rAbs were synthetized by reverse-engineering. Six different rAbs were produced: CR23003, CR23004, and CR23005 (from a patient vaccinated with Jcovden, Johnson & Johnson-Janssen (Beerse, Belgium)), CR22046, and CR22050 and CR22066 (from two different patients vaccinated with Vaxzevria, AstraZeneca (Cambridge, UK)). These rAbs were further characterized using anti-PF4 and anti-PF4/heparin IgG ELISAs, rapid anti-PF4 and anti-PF4/polyanion chemiluminescence assays, and PF4-induced platelet activation assay (PIPA) and their capacity to induce procoagulant platelets. Results: rAbs bound to PF4 alone, but not to PF4/polyanion complexes in rapid chemiluminescence assays. Chemiluminescence assays and both anti-PF4 IgG and anti-PF4 IgG/heparin ELISA showed concentration-dependent PF4 binding of all six rAbs, however, with different reactivities among them. PIPA showed a similar, concentration-dependent platelet activation pattern. rAbs varied in their reactivity and the majority of the tested rAbs were able to induce procoagulant platelets. Conclusions: The six rAbs derived from VITT patients reflect VITT-typical binding capacities and the ability to activate platelets. Therefore, these rAbs offer an attractive new option to study VITT pathophysiology.
Open AccessRecombinant Anti-PF4 Antibodies Derived from Patients with Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Facilitate Research and Laboratory Diagnosis of VITT
Background/Objectives: Adenoviral vector-based vaccines against COVID-19 rarely cause vaccine-induced immune thrombocytopenia and thrombosis (VITT), a severe adverse reaction caused by IgG antibodies against platelet factor 4 (PF4). To study VITT, patient samples are crucial but have become a scarce resource. Recombinant antibodies (rAbs) derived from VITT patient characteristic amino acid sequences of anti-PF4 IgG are an alternative to study VITT pathophysiology. Methods: Amino acid sequences of the variable region of immunoglobulin light and heavy chain of anti-PF4 IgG derived from VITT patients were obtained by mass spectrometry sequencing and rAbs were synthetized by reverse-engineering. Six different rAbs were produced: CR23003, CR23004, and CR23005 (from a patient vaccinated with Jcovden, Johnson & Johnson-Janssen (Beerse, Belgium)), CR22046, and CR22050 and CR22066 (from two different patients vaccinated with Vaxzevria, AstraZeneca (Cambridge, UK)). These rAbs were further characterized using anti-PF4 and anti-PF4/heparin IgG ELISAs, rapid anti-PF4 and anti-PF4/polyanion chemiluminescence assays, and PF4-induced platelet activation assay (PIPA) and their capacity to induce procoagulant platelets. Results: rAbs bound to PF4 alone, but not to PF4/polyanion complexes in rapid chemiluminescence assays. Chemiluminescence assays and both anti-PF4 IgG and anti-PF4 IgG/heparin ELISA showed concentration-dependent PF4 binding of all six rAbs, however, with different reactivities among them. PIPA showed a similar, concentration-dependent platelet activation pattern. rAbs varied in their reactivity and the majority of the tested rAbs were able to induce procoagulant platelets. Conclusions: The six rAbs derived from VITT patients reflect VITT-typical binding capacities and the ability to activate platelets. Therefore, these rAbs offer an attractive new option to study VITT pathophysiology.
- Open Access
Plant Cell Culture-Derived Saponin Adjuvant Enhances Immune Response Against a Stabilized Human Metapneumovirus Pre-Fusion Vaccine Candidate
Human metapneumovirus (HMPV) is a significant respiratory pathogen, particularly in vulnerable populations. Background: No vaccine for the prevention of HMPV is currently licensed, although several subunit vaccines are in development. Saponin-based adjuvant systems (AS), including QS-21, have transformed the field of subunit vaccines by dramatically increasing their potency and efficacy, leading to the development of several licensed vaccines. However, naturally sourced tree bark-extracted QS-21 faces supply and manufacturing challenges, hindering vaccine development. Objective: This study reports on an alternative plant cell culture system for the consistent production of highly pure QS-21. Method: We evaluated the efficacy of cultured plant cell (cpc)-produced QS-21 in a novel HMPV vaccine, formulating a recombinant pre-fusion stabilized HMPV F protein (preF) with cpcQS-21 and a synthetic toll-like receptor 4 (TLR4) agonist adjuvant formulation. Results: In mice, TLR4 agonist containing adjuvant formulations with plant cell-produced QS-21 performed equally to licensed adjuvant AS01 containing tree-bark-extracted QS-21 and demonstrated a significant increase in immunogenicity against HMPV preF compared to the unadjuvanted control. Conclusion: Our findings pave the way for a reliable, scalable, and sustainable source of pure QS-21, enabling the development of highly effective HMPV and other vaccines with significant public health impact.
Open AccessPlant Cell Culture-Derived Saponin Adjuvant Enhances Immune Response Against a Stabilized Human Metapneumovirus Pre-Fusion Vaccine Candidate
Human metapneumovirus (HMPV) is a significant respiratory pathogen, particularly in vulnerable populations. Background: No vaccine for the prevention of HMPV is currently licensed, although several subunit vaccines are in development. Saponin-based adjuvant systems (AS), including QS-21, have transformed the field of subunit vaccines by dramatically increasing their potency and efficacy, leading to the development of several licensed vaccines. However, naturally sourced tree bark-extracted QS-21 faces supply and manufacturing challenges, hindering vaccine development. Objective: This study reports on an alternative plant cell culture system for the consistent production of highly pure QS-21. Method: We evaluated the efficacy of cultured plant cell (cpc)-produced QS-21 in a novel HMPV vaccine, formulating a recombinant pre-fusion stabilized HMPV F protein (preF) with cpcQS-21 and a synthetic toll-like receptor 4 (TLR4) agonist adjuvant formulation. Results: In mice, TLR4 agonist containing adjuvant formulations with plant cell-produced QS-21 performed equally to licensed adjuvant AS01 containing tree-bark-extracted QS-21 and demonstrated a significant increase in immunogenicity against HMPV preF compared to the unadjuvanted control. Conclusion: Our findings pave the way for a reliable, scalable, and sustainable source of pure QS-21, enabling the development of highly effective HMPV and other vaccines with significant public health impact.
- Open Access
- 25 November 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-13
Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge
Vaccination with Ad26.RSV.preF, an Adenoviral serotype 26 vector encoding RSV F protein stabilized in its prefusion conformation, has previously shown to be immunogenic and protective in RSV seropositive adults and immunogenic in seropositive infants. Human and bovine RSV (bRSV) are genetically highly related and share many aspects of pathogenesis, epidemiology and clinical manifestations at young age. As such, infection of calves with bRSV represents a clinically relevant model with high translational value, enabling preclinical evaluation of Ad26.RSV.preF vaccine efficacy in seronegative young animals. Immunization of young calves with Ad26.RSV.preF induced antibodies neutralizing both human and bovine RSV as well as RSV-specific cellular responses. After bRSV challenge, placebo immunized calves showed viral replication in the respiratory tract, and developed fever and lethargy accompanied with severe respiratory distress, resulting in pre-termination of 7/8 calves. In contrast, all Ad26.RSV.preF immunized calves completed the study with only mild clinical symptoms, strongly and significantly diminished viral loads in nasopharynx and lungs, and only minimal lung pathology. Thus, Ad26.RSV.preF is immunogenic in young calves and efficacious in a stringent heterologous bRSV challenge model, demonstrating induction of broadly protective immunity against severe disease.
- 25 November 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-13
Open AccessAd26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge
Vaccination with Ad26.RSV.preF, an Adenoviral serotype 26 vector encoding RSV F protein stabilized in its prefusion conformation, has previously shown to be immunogenic and protective in RSV seropositive adults and immunogenic in seropositive infants. Human and bovine RSV (bRSV) are genetically highly related and share many aspects of pathogenesis, epidemiology and clinical manifestations at young age. As such, infection of calves with bRSV represents a clinically relevant model with high translational value, enabling preclinical evaluation of Ad26.RSV.preF vaccine efficacy in seronegative young animals. Immunization of young calves with Ad26.RSV.preF induced antibodies neutralizing both human and bovine RSV as well as RSV-specific cellular responses. After bRSV challenge, placebo immunized calves showed viral replication in the respiratory tract, and developed fever and lethargy accompanied with severe respiratory distress, resulting in pre-termination of 7/8 calves. In contrast, all Ad26.RSV.preF immunized calves completed the study with only mild clinical symptoms, strongly and significantly diminished viral loads in nasopharynx and lungs, and only minimal lung pathology. Thus, Ad26.RSV.preF is immunogenic in young calves and efficacious in a stringent heterologous bRSV challenge model, demonstrating induction of broadly protective immunity against severe disease.
- Open Access
- 14 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
A self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and naïve non-human primates
Newly approved subunit and mRNA vaccines for respiratory syncytial virus (RSV) demonstrate effectiveness in preventing severe disease, with protection exceeding 80% primarily through the generation of antibodies. An alternative vaccine platform called self-amplifying RNA (saRNA) holds promise in eliciting humoral and cellular immune responses. We evaluate the immunogenicity of a lipid nanoparticle (LNP)-formulated saRNA vaccine called SMARRT.RSV.preF, encoding a stabilized form of the RSV fusion protein, in female mice and in non-human primates (NHPs) that are either RSV-naïve or previously infected. Intramuscular vaccination with SMARRT.RSV.preF vaccine induces RSV neutralizing antibodies and cellular responses in naïve mice and NHPs. Importantly, a single dose of the vaccine in RSV pre-exposed NHPs elicits a dose-dependent anamnestic humoral immune response comparable to a subunit RSV preF vaccine. Notably, SMARRT.RSV.preF immunization significantly increases polyfunctional RSV.F specific memory CD4+ and CD8+ T-cells compared to RSV.preF protein vaccine. Twenty-four hours post immunization with SMARRT.RSV.preF, there is a dose-dependent increase in the systemic levels of inflammatory and chemotactic cytokines associated with the type I interferon response in NHPs, which is not observed with the protein vaccine. We identify a cluster of analytes including IL-15, TNFα, CCL4, and CXCL10, whose levels are significantly correlated with each other after SMARRT.RSV.preF immunization. These findings suggest saRNA vaccines have the potential to be developed as a prophylactic RSV vaccine based on innate, cellular, and humoral immune profiles they elicit.
- 14 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Open AccessA self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and naïve non-human primates
Newly approved subunit and mRNA vaccines for respiratory syncytial virus (RSV) demonstrate effectiveness in preventing severe disease, with protection exceeding 80% primarily through the generation of antibodies. An alternative vaccine platform called self-amplifying RNA (saRNA) holds promise in eliciting humoral and cellular immune responses. We evaluate the immunogenicity of a lipid nanoparticle (LNP)-formulated saRNA vaccine called SMARRT.RSV.preF, encoding a stabilized form of the RSV fusion protein, in female mice and in non-human primates (NHPs) that are either RSV-naïve or previously infected. Intramuscular vaccination with SMARRT.RSV.preF vaccine induces RSV neutralizing antibodies and cellular responses in naïve mice and NHPs. Importantly, a single dose of the vaccine in RSV pre-exposed NHPs elicits a dose-dependent anamnestic humoral immune response comparable to a subunit RSV preF vaccine. Notably, SMARRT.RSV.preF immunization significantly increases polyfunctional RSV.F specific memory CD4+ and CD8+ T-cells compared to RSV.preF protein vaccine. Twenty-four hours post immunization with SMARRT.RSV.preF, there is a dose-dependent increase in the systemic levels of inflammatory and chemotactic cytokines associated with the type I interferon response in NHPs, which is not observed with the protein vaccine. We identify a cluster of analytes including IL-15, TNFα, CCL4, and CXCL10, whose levels are significantly correlated with each other after SMARRT.RSV.preF immunization. These findings suggest saRNA vaccines have the potential to be developed as a prophylactic RSV vaccine based on innate, cellular, and humoral immune profiles they elicit.
- Open Access
- 30 September 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-7
Mosaic HIV-1 vaccine and SHIV challenge strain V2 loop sequence identity and protection in primates
The failure of human vaccine efficacy trials assessing a mosaic HIV-1 vaccine calls into question the translatability of preclinical SHIV challenge studies that demonstrated high efficacy of this vaccine in primates. Here we present a post hoc immune correlates analysis of HIV-1 Env peptide-binding antibody responses from the NHP13-19 study identifying the V2 loop as the principal correlate of protection in primates. Moreover, we found high V2 loop sequence identity between the Mos1 vaccine component and the SHIV challenge strain, while the vaccine showed considerably lower V2 identity to globally circulating HIV-1 sequences. Thus, the induction of immune responses against the V2 epitope, which had exceptional identity between the vaccine and challenge Env strains, may have contributed to the high protection in primates.
- 30 September 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-7
Open AccessMosaic HIV-1 vaccine and SHIV challenge strain V2 loop sequence identity and protection in primates
The failure of human vaccine efficacy trials assessing a mosaic HIV-1 vaccine calls into question the translatability of preclinical SHIV challenge studies that demonstrated high efficacy of this vaccine in primates. Here we present a post hoc immune correlates analysis of HIV-1 Env peptide-binding antibody responses from the NHP13-19 study identifying the V2 loop as the principal correlate of protection in primates. Moreover, we found high V2 loop sequence identity between the Mos1 vaccine component and the SHIV challenge strain, while the vaccine showed considerably lower V2 identity to globally circulating HIV-1 sequences. Thus, the induction of immune responses against the V2 epitope, which had exceptional identity between the vaccine and challenge Env strains, may have contributed to the high protection in primates.